Literature DB >> 21502619

Relevance of timing for determination of posaconazole plasma concentrations.

Werner J Heinz1, Janina Zirkel, Anna Kuhn, Diana Schirmer, Ulrike Lenker, Daniela Keller, Hartwig Klinker.   

Abstract

For posaconazole, drug monitoring is suggested, but the relevance of timing for the determination of posaconazole concentration (PC) remains unclear. We investigated the variation of PC before and 4 and 8 h after the administration of 400 mg of posaconazole. Mean concentrations were 645, 678, and 616 ng/ml. The differences between trough and maximum concentrations were below 20% in 17 and below 30% in 20 of 25 patients. Hence, untimed posaconazole plasma concentrations give reliable information for most patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502619      PMCID: PMC3122387          DOI: 10.1128/AAC.00062-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

Authors:  Angela Sansone-Parsons; Gopal Krishna; Angela Calzetta; David Wexler; Bhavna Kantesaria; Mitchell A Rosenberg; Marc A Saltzman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

5.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

Review 6.  Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  Angelika Böhme; Markus Ruhnke; Dieter Buchheidt; Oliver A Cornely; Herrmann Einsele; Ruxandra Enzensberger; Holger Hebart; Werner Heinz; Christian Junghanss; Meinolf Karthaus; William Krüger; Utz Krug; Thomas Kubin; Olaf Penack; Dietmar Reichert; Stefan Reuter; Gerda Silling; Thomas Südhoff; Andrew J Ullmann; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2008-10-14       Impact factor: 3.673

7.  Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Gopal Krishna; Malaz AbuTarif; Fengjuan Xuan; Monika Martinho; David Angulo; Oliver A Cornely
Journal:  Pharmacotherapy       Date:  2008-10       Impact factor: 4.705

8.  Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Bhavna Kantesaria
Journal:  Curr Med Res Opin       Date:  2007-05-11       Impact factor: 2.580

9.  Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction.

Authors:  Dominic Störzinger; Stefanie Swoboda; Christoph Lichtenstern; Carsten Müller; Markus A Weigand; Torsten Hoppe-Tichy
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

10.  Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

Authors:  Gopal Krishna; Monika Martinho; Pranatharthi Chandrasekar; Andrew J Ullmann; Hernando Patino
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705

View more
  9 in total

1.  Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.

Authors:  Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 2.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

4.  Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

Authors:  Aaron Cumpston; Ryan Caddell; Alexandra Shillingburg; Xiaoxiao Lu; Sijin Wen; Mehdi Hamadani; Michael Craig; Abraham S Kanate
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

5.  Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.

Authors:  Kim Vanstraelen; Juergen Prattes; Johan Maertens; Katrien Lagrou; Hélène Schoemans; Nele Peersman; Pieter Vermeersch; Koen Theunissen; Raf Mols; Patrick Augustijns; Pieter Annaert; Martin Hoenigl; Isabel Spriet
Journal:  Eur J Clin Pharmacol       Date:  2016-04-11       Impact factor: 2.953

6.  Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.

Authors:  Valeria A Bernardo; Shane J Cross; Kristine R Crews; Patricia M Flynn; James M Hoffman; Katherine M Knapp; Jennifer L Pauley; Alejandro R Molinelli; William L Greene
Journal:  Ann Pharmacother       Date:  2013-06-04       Impact factor: 3.154

7.  Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.

Authors:  Dong Sik Jung; Frank P Tverdek; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

8.  Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy.

Authors:  Adam J DiPippo; Patrick M McDaneld; Frank P Tverdek; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

9.  Experience using intravenous posaconazole in paediatric and young adult oncology patients.

Authors:  Arathi A Lambrix; Hope D Swanson; Jennifer L Pauley; Allison W Bragg; Delia C Carias; Melissa S Bourque; Yinmei Zhou; Cheng Cheng; William L Greene; Gabriela Maron
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.